Entrectinib
| CAS No. | 1108743-60-7 |
|---|---|
| MDL No. | MFCD28129099 |
| MF | C31H34F2N6O2 |
| MW | 560.60 |
| InChI Key | HAYYBYPASCDWEQ-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Entrectinib is an indazole derivative substituted with [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino at position 3 and 3,5-difluorobenzyl at position 5. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50: 0.1–1.7 nM) and is used to treat NTRK, ROS1, and ALK gene fusion-positive solid tumors. It functions as an antineoplastic agent, a receptor protein-tyrosine kinase inhibitor (EC 2.7.10.1), an antibacterial agent, and an apoptosis inducer. It is classified as a difluorobenzene, an indazole, a benzamide, an N-methylpiperazine, an oxane, a secondary amino compound, and a secondary carboxamide.
| CAS No. | 1108743-60-7 |
|---|---|
| Product Name | Entrectinib |
Biological Targets
ALK·NTRK1·NTRK2·NTRK3·ROS1
Associated Conditions
thyroid carcinoma·cancer·lymphoid neoplasm·neoplasm·central nervous system cancer·
* The information provided here is compiled from public sources and is for reference only.